N-(benzo[d][1,3]dioxol-5-yl)-7-chloroquinolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(benzo[d][1,3]dioxol-5-yl)-7-chloroquinolin-4-amine
• 英文别名: N-(benzo[1,3]dioxol-5-yl)-7-chloroquinolin-4-amine；N-(1,3-benzodioxol-5-yl)-7-chloroquinolin-4-amine
• 化学式: C₁₆H₁₁ClN₂O₂
• 分子量: 298.729
• InChiKey: UWSPBYIZLDIQHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  43.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,7-二氯喹啉 、 3,4-亚甲二氧基苯胺 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 N-(benzo[d][1,3]dioxol-5-yl)-7-chloroquinolin-4-amine
  参考文献：
  名称：

  一种N-苯基喹啉-4-胺类化合物及其应用

  摘要：

  一种N‑苯基喹啉‑4‑胺类化合物及其应用，此类化合物可抑制乙酰胆碱酯酶，结构式如下式

  公开号：

  CN115466211A

文献信息

• CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS
  申请人：Electrophoretics Limited

  公开号：EP2651404B1

  公开（公告）日：2015-10-14
• Novel therapeutic target for protozoal diseases
  申请人：Rathore Dharmender

  公开号：US20070148185A1

  公开（公告）日：2007-06-28

  A novel Hemozoin Detoxification Protein (HDP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. HDP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, HDP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on HDP, or antigenic epitopes of HDP, either alone or in combination with other parasite antigens. Methods for the development and use of compounds that inhibit the catalytic activity of HDP, and diagnostic and laboratory methods utilizing HDP are also provided. HDP is also referred to herein as Fasciclin Related Adhesive Protein (FRAP).
• CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS
  申请人：Sheridan Joseph M.

  公开号：US20140018540A1

  公开（公告）日：2014-01-16

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Electrophoretics Limited

  公开号：US20160354375A1

  公开（公告）日：2016-12-08

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US20200181089A1

  公开（公告）日：2020-06-11

  The present invention relates to a compound of general formula (I): said compound being as defined in claim ( 1 ). The invention also relates to a pharmaceutical composition comprising: —a compound of general formula (I) as defined in claim ( 12 ) and, —at least one antibody selected from an anti-PD1 antibody, an anti-CTLA4 antibody, an anti-PD-L1 antibody and a mixture of two or more thereof. The invention also relates to a compound of general formula (I) as defined in claim ( 17 ) for use in the treatment of cancer, said cancer being preferably selected from melanoma, bladder, kidney, prostate, colon, lung, breast and blood cancer.